project . 2021 - 2025 . On going

INCITE

Immune Niches for Cancer ImmunoTherapy Enhancement
Open Access mandate for Publications and Research DataOpen Access mandate for ... European Commission
  • Funder: European CommissionProject code: 964955 Call for proposal: H2020-FETOPEN-2018-2019-2020-01
  • Funded under: H2020 | RIA Overall Budget: 3,998,660 EURFunder Contribution: 3,998,660 EUR
  • Status: On going
  • Start Date
    01 May 2021
    End Date
    30 Apr 2025
  • Detailed project information (CORDIS)
Description
Cancer is rapidly becoming the most frequent cause of morbidity and mortality in the EU, accounting for a quarter of all deaths in EU. Without breakthroughs in treatment, cancer is likely to remain one of the biggest killers in the 21st century. Immunotherapy of cancer by checkpoint inhibitors, vaccines or adoptive T cell therapy is coming of age and has the potential to cure cancer, but is still hampered by some major limitations. For instance, Adoptive Cell Therapy (ACT) with unmanipulated or engineered T cells (TCR-transgenic and CAR-T cells) has indeed demonstrated success in the treatment of patients affected by leukemias, but is much less effective against...
Description
Cancer is rapidly becoming the most frequent cause of morbidity and mortality in the EU, accounting for a quarter of all deaths in EU. Without breakthroughs in treatment, cancer is likely to remain one of the biggest killers in the 21st century. Immunotherapy of cancer by checkpoint inhibitors, vaccines or adoptive T cell therapy is coming of age and has the potential to cure cancer, but is still hampered by some major limitations. For instance, Adoptive Cell Therapy (ACT) with unmanipulated or engineered T cells (TCR-transgenic and CAR-T cells) has indeed demonstrated success in the treatment of patients affected by leukemias, but is much less effective against...
Any information missing or wrong?Report an Issue